0
Deep & Emerging Tech·November 11, 2026·1 min read

Google’s AlphaGenome 2 zooms in on the cellular roots of disease

Share

A high-resolution model of how DNA changes affect different cell types compresses years of wet-lab iteration into in silico passes. Drug discovery teams that can integrate this kind of tooling into their pipelines will be able to kill bad hypotheses earlier and reallocate capital faster.

Deep & Emerging Tech

OKX and ICE's joint venture OKXICE plans to launch a US tokenized stock venue on November 23 and list 70+ assets; 56 of the 62 companies it targeted objected

Tokenized equities are running straight into issuer resistance—56 of 62 targeted companies objected—which means the near-term action will be in regulatory arbitrage and niche assets, not blue-chip stocks. If you’re a broker or exchange operator, treat tokenization as an infrastructure experiment for now, not a core revenue line.